Targeting Gene Regulation in Disease
To find innovative solutions for diseases of aberrant gene control by advancing the science of RNA and chromatin regulation, developing new technological platforms, and discovering early stage therapeutics.
To build a collaborative therapeutic center dedicated to excellence in studying and drugging gene regulation.
what’s trending: CENTER NEWS AND INSIGHTS
recent media & publications
Group Leader, Dr. Calla Olson’s paper on the development of a selective CDK7 inhibitor was published in Cell Chemical Biology. Collaborators from the Nathanael Gray Lab at Dana-Farber Cancer Institute and Charles Lin Lab at Baylor College of Medicine are among contributors.
upcoming events and deadlines
September 20, 2019: RNA and Chromatin Group talks resume!
October 9, 2019: Applications for faculty positions due.
To achieve our goal of translating fundamental discoveries in gene regulation into therapeutics, we will:
Align chemical biology, genomics, and computational biology for rigorous and focused therapeutic development
Recruit talented interdisciplinary scientists to rapidly discover new medicines
Bridge biological and chemical technology developments with the expertise of scientist and physicians at Baylor College of Medicine to impact diseases of altered gene control